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Biosynthesis, Structure, and Biological Activities of 
Envelope Protein gp65 of Murine Coronavirus 
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Department of Microbiology, University of Southern California, School of Medicine, Los Angeles, California 90033 
Received June 2 1 I 1989; accepted August 25, 1989 
We have previously shown that gp65 (E3) is a virion structural protein which varies widely in quantity among different 
strains of mouse hepatitis virus (MHV). In this study, the biosynthetic pathway and possible biological activities of this 
protein were examined. The glycosylation of gp65 in virus-infected cells was inhibited by tunicamycin but not by monen- 
sin, suggesting that it contains an /V-glycosidic linkage. Glycosylation is cotranslational and appears to be complete 
before the glycoprotein reaches the Golgi complex. Pulse-chase experiments showed that this protein decreased in 
size after 30 min of chase, suggesting that the carbohydrate chains of gp65 undergo trimming during its transport 
across the Golgi. This interpretation is supported by the endoglycosidase treatment of gp65, which showed that the 
peptide backbone of gp65 did not decrease in size after pulse-chase periods. This maturation pathway is distinct from 
that of the El or E2 glycoproteins. Partial endoglycosidase treatment indicated that gp65 contains 9 to 10 carbohydrate 
side chains; thus, almost all of the potential glycosylation sites of gp65 were glycosylated. In vitro translation studies 
coupled with protease digestion suggest that gp65 is an integral membrane protein. The presence of gp65 in the virion 
is correlated with the presence of an acetylesterase activity. No hemagglutinin activity was detected. o 1989 Academic 
Press, Inc. 
INTRODUCTION 
Mouse hepatitis virus (MHV), a member of the Coro- 
naviridae family, is an enveloped virus with a positive- 
sensed RNA genome of more than 6 X lo6 molecular 
weight (Lai and Stohlman, 1978; Wege et a/., 1978). 
The virion particle is composed of three structural pro- 
teins: two glycosylated envelope proteins, gpl8OIgp90 
(E2) and gp23 (El), and a phosphorylated nucleocapsid 
protein pp60 (N). The E2 protein forms the spikes on 
the surface of virion, is responsible for viral interaction 
with target cells and fusion activity, and also elicits neu- 
tralizing antibodies (Sturman and Holmes, 1983). 
Monoclonal antibodies against E2 alter the pathoge- 
nicityof MHV(Fleming eta/., 1986; Dalziel eta/., 1986). 
El is a transmembrane matrix protein (Sturman et al., 
1980; Rottier et al., 1984, 1986) the function of which 
is not yet clear. Some monoclonal antibodies against 
El can also alter the pathogenicity of the virus (Fleming 
eta/., 1989). The N protein is a phosphotylated nucleo- 
capsid protein (Stohlman and Lai, 1979) which inter- 
acts with virion RNA (Sturman et al., 1980; Baric et al., 
1988). Some strains of MHV, e.g., JHM or MHV-S, con- 
tain an additional glycoprotein gp65 (Lai and Stohlman, 
1981; Siddell, 1982; Makino et al., 1983). Since bro- 
melain treatment of JHM virion removed gp65, it has 
been suggested that this protein is also an envelope 
’ To whom reprint requests should be addressed. 
protein, part of which is exposed on the viral surface of 
this virus (Makino et al., 1983). 
The structural proteins of MHV are translated from 
virus-specific monocistronic mRNAs in the virus-in- 
fected cells (Rottier et al., 198 1; Leibowitz et al., 1982). 
These mRNAs have a 3’-coterminal nested-set struc- 
ture (Lai et a/., 1981; Leibowitz et al., 1981). Only the 
5’-terminal unique region of each mRNA is used for 
translation (Leibowitz et al., 1982; Siddell, 1983). The 
E2 protein is translated from mRNA 3, and glycosylated 
at asparagine residues via N-glycosidic bonds (Holmes 
et a/., 1981; Rottier et al., 1981). It is first synthesized 
as a ~110 precursor, and glycosylated to gpl50 and 
then to gpl80 (Siddell et a/., 198 1; Rottier et a/., 1981). 
It is subsequently cleaved into two gp90 subunits (Stur- 
man et al., 1985). This cleavage is required for viral in- 
fectivity and is carried out by cellular proteases (Storz 
et a/., 1981; Yoshikura and Tajima, 1981; Sturman et 
al., 1985). In contrast, El protein is an O-linked glyco- 
protein, which is probably glycosylated in the Golgi 
complex post-translationally (Holmes et a/., 1981; Nie- 
mann and Klenk, 1981; Niemann et al., 1984; Rottier 
and Rose, 1987). The glycosylation of the E 1 protein is 
resistant to tunicamycin but is sensitive to monensin, 
which acts at the Golgi complex level (Niemann et al., 
1982). In contrast to what is known about El and E2, 
the biosynthetic pathway of gp65 in MHV-infected 
cells is not yet clear. Recently we have shown that 
gp65 is translated from a new mRNA designated 
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mRNA 2b, which is synthesized by only a few isolates 
of JHM strains of MHV (Makino and Lai, 1989; Shieh et 
al., 1989). This mRNA corresponds to an open reading 
frame (ORF) 2b which encodes gp65 (Shieh et al., 
1989). The unique aspect of this protein is that its ex- 
pression is variable among different MHV strains and 
is regulated by the sequences of leader RNA at the 5’- 
end of genomic RNA and the intergenic region preced- 
ing the ORF 2b. For instance, JHM(3) virus, which con- 
tains three UCUAA repeats at the 3’-end of leader RNA, 
makes only a small quantity of gp65 (Makino and Lai, 
1989; Shieh eta/., 1989). In contrast, JHM(2) virus with 
two UCUAA repeats makes an abundant quantity of the 
protein (Shieh et a/., 1989). Although the genomic RNA 
of the A59 strain of MHV contains ORF 2b and two 
UCUAA repeats, it lacks both correct transcriptional 
and correct translational start signals for this gene, re- 
sulting in the absence of gp65 in A59 virus (Luytjes et 
al., 1988; Shieh et a/., 1989). 
The gp65 protein has also been detected in another 
coronavirus, bovine coronavirus (BCV) (King and Brian, 
1982). This protein, termed E3, contains both an ester- 
ase activity, which is similar to the receptor-destroying 
activity of influenza C virus (Vlasak et al., 1988a), and 
a hemagglutinin activity (King et a/., 1985). Signifi- 
cantly, the predicted sequence of gp65 of MHV is ho- 
mologous to the hemagglutinin protein of influenza C 
virus (Luytjes et a/., 1988) although hemagglutinin ac- 
tivity has not been demonstrated for MHV (Talbot 
1989). The presence of this protein in certain strains of 
coronaviruses raises the question whether the added 
biological activity of this protein contributes to the bio- 
logical or pathogenic properties of the viruses. To 
answer such a question, we characterized the bio- 
chemical properties of gp65 of MHV. In this report, we 
determined its structure, biosynthetic pathway, and 
esterase activity. 
MATERIALS AND METHODS 
Virus and cells 
The plaque-cloned JHM(2), which contains two 
UCUAA repeats at the 3’-end of leader sequence (Ma- 
kino and Lai, 1989) was used for most of the experi- 
ments described in this study. Two other MHV isolates, 
JHM(3), which contains three UCUAA repeats (Makino 
and Lai, 1989) and A59 strains were also used. Vi- 
ruses were propagated on DBT cell, a mouse astrocy- 
toma cell line (Hirano et a/., 1974) according to the 
methods described previously (Makitio et a/., 1984). 
Preparation of rabbit antiserum specific 
for JHM(2) virion proteins 
JHM(2) virus was purified from approximately 1 liter 
of media from infected DBT cells according to the pub- 
lished method (Makino et a/., 1983). Briefly, virus parti- 
cles were purified by discontinuous and continuous su- 
crose gradients, pelleted by centrifugation in a Beck- 
man SW41 rotor at 40,000 rpm for 2 hr, and then 
suspended in TE buffer (0.01 M Tris-HCI, pH 7.4 and 
1 mn/r EDTA) containing 0.1 %I SDS. Purity of virus was 
examined by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) and staining with Coomassie blue. The 
purified virus was injected into rabbits intramuscularly 
three times with 2-week intervals. The first injection 
was made with complete Freund’s adjuvant, whereas 
second and third ones were with incomplete adjuvant. 
After checking the titer of antiviral antibody by ELISA, 
rabbits were bled. Serum was complement-inactivated 
at 56” for 30 min, adsorbed with uninfected DBT cells, 
and filtered before use. 
35S-labeling of intracellular proteins and 
preparation of cell extracts 
Confluent monolayers of DBT cells (1.5 X 1 O6 cells) 
were infected with virus at a multiplicity of infection of 
2. After 1 hr adsorption at 37”, virus inoculum was re- 
placed with minimum essential media (MEM) contain- 
ing 5% dialyzed fetal calf serum (FCS). At 8.5 hr postin- 
fection, medium was changed to methionine-free 
MEM containing 2% dialyzed FCS. After 30-min starva- 
tion for methionine, 35S-translabel (1 193 Ci/mmol; ICN 
Biochemicals) was added to a final concentration of 50 
&i/ml. Cells were pulse-labeled for either 20 or 5 min 
and chased for different periods of time. Cells were 
then placed on ice, washed three times with cold phos- 
phate-buffered saline (PBS), and lysed with 400 ~1 of 
lysis buffer (1% Triton X-l 00, 0.5% sodium deoxycho- 
late, and 0.1% SDS in PBS) containing 1 mll/l phenyl 
methyl sulfonyl fluoride (PMSF). Cell lysate was imme- 
diately passed through a 1 g-gauge syringe needle five 
times and centrifuged at 12,000 g for 10 min at 4”. The 
supernatant fluid was stored at -70”. 
lmmunoprecipitation and SDS-PAGE 
Each cytoplasmic lysate was incubated with rabbit 
hyperimmune serum prepared against purified JHM(2) 
at 4” for 2 hr. Protein A (Pansorbin, Calbiochem) (10% 
suspension in 0.05% NP-40) was then added to the 
reaction mixture, which was further incubated at 4’for 
2 hr. Precipitates were washed with lysis buffer several 
times. The final pellet was suspended in 2X sample 
buffer (0.06 NITris-HCI, 2% SDS, 25% glycerol, 5% 2- 
mercaptoethanol, and 0.1 O/O bromphenol blue), heated 
at 95” for 3 min, and centrifuged at 12,000 g for 5 min. 
The supernatants were electrophoresed on 7.5 to 15% 
gradient polyacrylamide gel containing 0.1% SDS. 
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Tunicamycin and monensin treatments 
At 3 hr postinfection, tunicamycin (Sigma) was 
added to media to a final concentration of 0.3-l pg/ml. 
At 8 hr p.i., cells were pulse-labeled in the presence of 
tunicamycin with 35S-translabel for 20 min and pro- 
cessed for immunoprecipitation as described above. 
For monensin treatment, monensin (Sigma) was added 
to the media to a final concentration of 1 Od7 to 1 Oe5 M 
at 3 hr p.i. At 8 hr p.i., cells were pulse-labeled with 35S- 
translabel for 20 min and then chased with cold methi- 
onine for 2 hr before immunoprecipitation. 
Endoglycosidase H treatment 
After immunoprecipitation of infected cell lysates, 
the immune complexes bound to Pansorbin were 
eluted by heating in 0.5% SDS and 50 mM Tris-HCI, 
pH 7.5, at 95” for 4 min (Kakach eta/., 1989) and centri- 
fuged. The supernatant was mixed with an equal vol- 
ume of 1 M sodium citrate buffer (pH 7.0) containing 1 
mM PMSF and 1 to 25 mU of endoglycosidase H (Boe- 
hringer-Mannheim) and incubated at 37” for different 
periods of time ranging from 1 min to 16 hr. After incu- 
bation, the reaction mixture was mixed with an equal 
volume of 2x sample buffer and heated at 95” for 4 min 
before SDS-PAGE analysis. 
In vitro transcription and translation 
Recombinant plasmid pT7(2B) (Shieh et a/., 1989) 
was linearized by digestion with EcoRI or BarnHI and 
transcribed in vitro with T7 RNA polymerase as pre- 
viously described (Soe et a/., 1987; Tabor and Richard- 
son, 1985). The resulting RNA was translated in 
mRNA-dependent rabbit reticulocyte lysate (Promega 
Biotech) in the presence of [35S]methionine. Reactions 
were carried out in a final volume of 25 ~1 under condi- 
tions recommended by the manufacturer. Where spec- 
ified, 2 ~1 of canine pancreatic microsomal membranes 
(Promega Biotech) were added to the reaction mix- 
tures. Translation products were analyzed by electro- 
phoresis on 10% polyacrylamide gels containing 1% 
SDS (Laemmli, 1970). 
Protease digestion 
Translation mixtures were diluted 1:2 with 50 mlVI 
Tris-HCI buffer, pH 7.4, containing 100 ml\/l NaCl and 
3 mg/ml Pronase (Sigma), and incubated at 0” for 30 
min. Proteolysis was terminated by treatment with a 
protease-inhibitor cocktail containing 10 mM PMSF, 
2.5 mM EDTA, 1.4 mg/ml Pepstatin A, and 3 mg/ml 
Aprotinin. Samples were analyzed by SDS-PAGE. 
Acetylesterase assays 
Media collected at 14 hr p.i. from the virus-infected 
cells were precipitated by ammonium sulfate (Makino 
et a/., 1984). Virus precipitates were suspended in 
PBS, and incubated with 1 mr2/1 p-nitrophenylacetate 
(Sigma) at room temperature. Hydrolysis of the sub- 
strate was monitored at 400 nm at 2-min intervals as 
previously described (Vlasak et al., 1988a), using a 
chart recorder. Media from mock-infected cells were 
also precipitated with ammonium sulfate as a control. 
The background counts of this control were subtracted 
from those of virus samples. An aliquot of virus precipi- 
tate was used for plaque assay to determine virus titers 
of each virus preparation. The O.D.,,, values of each 
virus were normalized with respect to the virus titer 
used. 
Hemagglutination assay 
Fresh red blood cells from mice (BALB/C and C57BL) 
were washed and resuspended in PBS to a final con- 
centration of 0.5%, and then aliquoted (50 ~11 into each 
well) into V-shaped microtiter plates. Equal volumes of 
a series of twofold dilutions of the different virus prepa- 
rations were added to each well. Plates were incubated 
at 4’ overnight before results were read. 
RESULTS 
Detection of intracellular virus-specific gp65 
To study the structure, biosynthesis, and possible 
biological activities of gp65, we first determined the in- 
tracellular form of gp65 in cells infected with different 
strains of MHV, including A59 and two strains of JHM, 
JHM(2), and JHM(3), which differ in the number of 
UCUAA repeats in the leader sequence (Makino and 
Lai, 1989; Shieh et al., 1989). Cells were pulse-labeled 
with 35S-translabel for 20 min, immunoprecipitated with 
antibodies made against JHM(2) virion which contains 
a large quantity of gp65 (Shieh et a/., 1989) and then 
analyzed by SDS-PAGE. As can be seen from Fig. 1, 
JHM(2) synthesizes a prominent species of 65-kDa pro- 
tein in addition to N, El, and E2 proteins. This virus has 
been shown to synthesize a large amount of mRNA 2b 
in infected cells (Makino and Lai, 1989; Shieh et a/., 
1989). In contrast, JHM(3), which synthesizes a very 
small amount of mRNA 2b, synthesized a compara- 
tively smaller quantity of gp65. This is in agreement 
with the previous finding that mRNA 2b is the mRNA 
for gp65 (Makino and Lai, 1989; Shieh et a/., 1989). 
Surprisingly, A59, which does not synthesize mRNA 2b 
(Makino and Lai, 1989) and does not contain ORF 2b 
with an initiator AUG (Luytjes et a/., 1988) also makes 
a small amount of gp65. Since this protein was precipi- 
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protein was detected. In contrast, the size of gp23(El) 
was not affected by the presence of tunicamycin, since 
it is an O-linked glycoprotein (Niemann and Klenk, 
1981; Holmes et al., 1981; Rottier and Rose, 1987). It 
is interesting to note that the 45-kDa protein detected 
in the presence of tunicamycin appears to consist of 
two bands, in agreement with the previous in vitro 
translation studies of mRNA 2b (Shieh eta/., 1989). The 
significance of this finding is unknown at the present 
time. 
FIG. 1. Intracellular viral proteins of JHM(2), JHM(B), and A59. Virus- 
infected cells were radiolabeled with 35S-translabel at 9 hr p.i. for 20 
min. Cell lysates were immunoprecipitated with anti-JHM(2) rabbit 
serum and analyzed by SDS-PAGE on 7.5 to 15% gradient polyacry- 
amide gel. Gels were overexposed to reveal gp65 in A59-infected 
cells. M, “C-protein molecular weight markers. 
Another inhibitor of glycoprotein transport, monen- 
sin, affected the synthesis of the three viral glycopro- 
teins differently. As shown in Fig. 3, monensin reduced 
the size of El. This result is in agreement with the pub- 
lished finding that El glycosylation occurs in Golgi 
complex (Niemann et a/., 1982; Rottier and Rose, 
1987). In contrast, E2 maturation occurred even in the 
presence of monensin. However, the size of the mature 
E2(gp90) was slightly smaller than that of E2 synthe- 
sized in the absence of monensin. The two protein 
bands corresponding to E2 (90K) probably represent 
different glycosylation states of the protein. This result 
indicates that the final carbohydrate residues on E2 
glycoproteins are added in the Golgi apparatus and 
that incomplete glycosylation does not interfere with 
tated with JHM(2)-gp65-monospecific antibodies (data 
not shown), it is probably related to the JHM-specific 
gp65. The significance of this protein in A59 will be dis- 
cussed later. 
12345 
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The relative amount of gp65 in infected cells is con- 
siderably higher than that in virion (Shieh et a/., 1989) 
suggesting that the incorporation of gp65 into virion is 
poor. 
-6~65 
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Biosynthesis of gp65 in the presence of 
tunicamycin and monensin 
To understand the biosynthetic pathway of gp65, we 
studied the synthesis of viral glycoproteins in JHM(2) 
virus-infected cells in the presence of different inhibi- 
tors of glycosylation. Tunicamycin has been shown to 
inhibit the synthesis of ALglycosidic bond-linked glyco- 
proteins (Takatsuki et al., 1975). As shown in Fig. 2, 
tunicamycin inhibited the synthesis of gp65. Instead, a 
protein of 45 kDa was detected. This result is consis- 
tent with the previous in vitro translation studies which 
indicated that the peptide portion of this glycoprotein 
is of 45 kDa (Shieh eta/., 1989). Furthermore, it demon- 
strates that gp65 is an N-linked glycoprotein. In agree- 
ment with the published data (Niemann and Klenk, 
198 l), the glycosylated E2 was not detectable in the 
presence of tunicamycin. instead, a pl 10 precursor 
+E1(2lK) 
FIG. 2. Effects of tunicamycin treatment on the synthesis of intra- 
cellular viral proteins. JHM(2)-infected DBT cells were radiolabeled 
with ?S-translabel at 9 hr p.i. for 20 min in the presence of different 
concentrations of tunicamycin. Cell lysates were immunoprecipi- 
tated with anti-JHM(2) rabbit serum. Lane 1, mock-infected cells; 
lane 2, JHM(2)infected cells without tunicamycin; lane 3, JHM(2)- 
infected cells with tunicamycin 0.3 rglml; lane 4, JHM(2)-infected 
cells with tunicamycin 0.6 pg/ml; lane 5, JHM(2)-infected cells with 
tunicamycin 1 pg/ml. 
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FIG. 3. Effects of monensin treatment on the synthesis of intracel- 
lular viral proteins. JHM(Z)-infected cell lysate was prepared as de- 
scribed under Materials and Methods and immunoprecipitated with 
anti-JHM(2) rabbit serum. M, Y-protein molecular weight markers; 
lane 1, mock-infected; lane 2, ZO-min [?S] pulse-labeling at 9 hr p.i.; 
lane 3, 2-hr chase after 20 min of pulse-labeling; lane 4, the same 
condition as lane 3, but in the presence of monensin (1 Om5 M). 
the cleavage of gpl80 into gp90. In contrast, the size 
of gp65 was not affected by the presence of monensin 
(Fig. 3, lanes 3 and 4) suggesting that the glycosyla- 
tion of gp65 was completed before the protein was 
transported into Golgi complex. 
Careful examination of Fig. 3 also revealed that, after 
2 hr of chase with cold methionine, gp65 slightly de- 
creased in size (fig. 3, lanes 2 and-3) suggesting that 
further processing of gp65 takes place after its glyco- 
sylation (see also Fig. 4). Monensin did not affect this 
processing (Fig. 3, lane 4). 
Pulse-chase studies of g.p65 biosynthesis 
To further study the biosynthetic pathway of gp65, 
additional pulse-chase experiments were carried out. 
Figure 4 shows that a fully glycosylated gp65 could be 
detected after 5 min of pulse-labeling. No precursor 45- 
kDa protein could be detected, even after pulse-label- 
ing for as short as 2 min (data not shown). This result 
suggests that glycosylation of gp65 may be cotransla- 
tional. After 30 min of chase, a slight decrease of gp65 
size was noticeable (Fig. 4, lane 4). The size reduction 
of gp65 reached a maximum after 1 hr of chase (lane 
5). These kinetics of gp65 processing suggest that a 
trimming of carbohydrate or peptide of gp65 occurred 
in the Golgi complex (Johnson and Spear, 1983). In 
~123456 
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contrast, El was not glycosylated during the 5-min 
pulse-labeling period. The glycosylation of El did not 
begin to occur until after 30 min of chase period. The 
fully glycosylated El could not be detected until after 2 
hr of chase. This result is consistent with the monensin 
studies which suggest that the glycosylation of El oc- 
curs in the Golgi complex. The glycosylation of E2 oc- 
curred rapidly during the 5-min pulse-labeling period, 
resulting in the detection of gpl50. The cleaved E2 
(gp90) could not be observed until after 1 hr of chase 
period. Thus, the final glycosylation of E2 probably also 
occurred in the Golgi complex. 
Removal of carbohydrates by endoglycosidase 
treatments 
To determine whether the decrease in the size of 
gp65 during chase period is because of trimming of 
carbohydrate or cleavage of peptide backbone, we 
treated the intracellular viral glycoproteins with either 
endoglycosidase H or endoglycosidase F to remove 
carbohydrate side chains. As shown in Fig. 5, the endo 
H treatment reduced gp65 to a size of 45 kDa, indicat- 
ing that most of the carbohydrate side chains have 
been removed. The sizes of endo H-treated gp65 were 
identical between samples chased for 10 and 60 min, 
even though the untreated gp65 at these two time 
FIG. 4. Pulse-chase labeling of JHM(2)-infected DBT cells. At 9 hr 
pi., JHM(2)Gnfected DBT cells were pulse-labeled in medium con- 
taining 150 &i/ml of %S-translabel for 5 min and chased with cold 
methionine for various periods of time. Cell extracts were immuno- 
precipitated with anti-JHM(2) rabbit serum. M, Y-protein molecular 
weight markers; lane 1, mock infection; lane 2, 5-min labeling without 
chase; lane 3, lo-min chase after labeling; lane 4, 30-min chase; 
lane 5. 1-hr chase; lane 6, 2-hr chase. 
688 YOKOMORI ET AL 
points differed in size. This result suggests that the de- 
crease in the size of gp65 during the chase period is 
because of trimming of carbohydrate side chains. It is 
also noted that two proteins of approximately 45 kDa 
were detected after endo H treatment. Prolonged treat- 
ment (16 hr) and higher endo H concentration (25 mu) 
did not eliminate either of these two proteins (data not 
shown). Thus, these two proteins were not the result 
of incomplete endo H treatment. Similar results were 
obtained after treatments with endoglycosidase F (data 
not shown). The significance of these two proteins will 
be discussed later. 
It has previously been determined that gp65 of JHM 
contains 10 potential N-glycosylation sites (Shieh eta/., 
1989). To determine the actual number of carbohy- 
drate side chains in this protein, we treated gp65 with 
endoglycosidase H under very mild conditions to 
achieve partial and stepwise removal of carbohydrate 
side chains. As shown in Fig. 6, at least 9 or 10 distinct 
protein species could be detected, ranging from the 
complete gp65 to the final digestion products. These 
products most likely represent the intermediates of 
endo H-digestion products. This result suggests that 
most, if not all, of the potential IV-glycosylation sites are 
glycosylated. 
Topology of gp65 in the membrane 
Since gp65 contains hydrophobic domains at both 
N- and C-termini (Shieh er al., 1989) it is very likely an 
integral membrane protein. To determine the likely to- 
pology of gp65 in the membrane, we performed in vitro 
translation of the ORF 2b RNA transcribed from a pT7 
plasmid construct. Translation was performed in the 
presence of canine pancreatic microsomal mem- 
branes, and translation products were digested with 
Pronase to remove the portion of proteins not translo- 
cated into the lumen of microsomal membranes. As 
shown in Fig. 7, in vitro translation of this RNA yielded 
a primary translation product of 45 kDa, which was gly- 
cosylated to a protein of 65 kDa in the presence of mi- 
crosomal membranes. The latter protein was con- 
verted to a protein of 35 kDa after Pronase digestion. 
This result suggests that gp65 is indeed a membrane 
protein with roughly a 35-kDa portion protruding into 
the lumen of microsomal membrane. Translation of a 
truncated RNA representing the 5’-end 768 nucleo- 
tides of ORF 2b resulted in a primary translation prod- 
uct of 28 kDa which corresponds to the N-terminal por- 
tion of gp65. In the presence of microsomal mem- 
brane, this protein was converted to a protein of 33 
kDa. Thus, the N-terminal portion alone of gp65 has 
the capacity to be translocated across the membrane. 
1234M 
FIG. 5. Endoglycosidase H treatment of intracellular viral glycopro- 
teins. JHM(2)-infected cells were pulse-labeled with “S-translabel for 
5 min and chased for 10 min or 1 hr. Lysates were immunoprecipi- 
tated, dissolved in 50 mM Tris-HCI (pH 7.4) containing 0.5% SDS, 
and boiled for 4 min before endoglycosidase H treatment (3 mu, at 
37” for 16 hr). Lane 1, 5-min pulse, 1 0-min chase, endoglycosidase 
H (3 mu); lane 2, 5-min pulse, 1 0-min chase, no endoglycosidase H 
treatment; lane 3, 5-min pulse, I-hr chase, endoglycosidase H (3 
mu); lane 4, 5-min pulse, 1-hr chase, no endoglycosidase H treat- 
ment: M, %protein molecular weight markers. 
Esterase and hemagglutinin activities of gp65 
The gp65 (E3) of BCV has been shown to contain 
both hemagglutinin (King et al., 1985; Parker et a/., 
1989) and esterase activities (Vlasak et a/., 1988a). We 
therefore determined whether gp65 of MHV also con- 
tains similar activities. We purified JHM(2), JHM(3), and 
A59, which contain different amounts of gp65 in the 
virion, and tested the presence of esterase activities, 
using p-nitrophenylacetate as a substrate. Figure 8 
shows that, although both JHM strains could hydro- 
lyze p-nitrophenylacetate, JHM(2) has a considerably 
higher activity. Since the only difference among these 
three viruses in virion structural proteins is the amount 
of gp65 (Fig. 1) (Shieh eta/., 1989) this result is consis- 
tent with gp65 being responsible for the esterase activ- 
ity. A59 has a very low but detectable esterase activity, 
consistent with the presence of a trace amount of gp65 
in the virion. 
We have also tested the possible presence of a hem- 
agglutinin activity of these three strains of MHV, using 
red blood cells from several different animal species, 
including mouse, sheep, chicken, bovine, guinea pig, 
rat, and human. While BCV was demonstrated to hem- 
agglutinate all of these red blood cells, none of the 
MHV strains tested agglutinated these cells (data not 
shown). Thus, MHV gp65 does not possess hemagglu- 
tinin activities detectable under these conditions. 
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FIG. 6. Partial endoglycosidase H treatment of intracellularviral gly- 
coproteins. Infected cell lysate labeled with 35S-translabel for 5 min 
and chased for 10 min as shown in lane 1 of Fig. 5 was treated with 
endoglycosidase H (0.5 mu) for 4 (lane 1) and 5 min (lane 2), respec- 
tively. Lane 3 is the untreated sample. 
DISCUSSION 
gp6.5 (E3) is an optional structural protein among co- 
ronaviruses. It has been detected in BCV (King et al., 
1985), human coronavirus OC43 (Hogue and Brian, 
1986), and turkey coronavirus (Dea and Tijssen, 1988) 
and is absent in avian infectious bronchitis virus (IBV) 
(Cavanagh, 1981). The best characterized gp65 is the 
one in BCV. It is a membrane glycoprotein, which forms 
short spikes on virion surface (King et a/., 1985). It con- 
tains hemagglutinin (King et a/., 1985; Parker et al., 
1989) and esterase activities (Vlasak et al., 1988a). 
Some strains of MHV also contain gp65 (Lai and Stohl- 
man, 1981; Siddell, 1982; Makino et al., 1983). Even 
within a particular strain, e.g., JHM, the amount of gp65 
appeared to be variable with different virus stocks. Be- 
cause of this variability and because no known viral 
genes or mRNAs were capable of encoding this pro- 
tein, the identity of this glycoprotein in MHV has long 
been in question. Recently, our laboratory has identi- 
fied a genetic region in MHV genome capable of en- 
coding gp65 (Shieh eta/., 1989). Furthermore, we have 
determined the molecular basis of differential transcrip- 
tion of this gene in different MHV strains (Makino and 
Lai, 1989; Shieh et al., 1989). Thus, this glycoprotein 
is an optional protein among MHVs. However, our cur- 
rent study showed that even A59 strain, which does 
not have a complete gene 2b (Luytjes eta/., 1988), syn- 
thesizes a small amount of gp65 (Shieh et a/., 1989). 
Therefore, this protein may possibly be indispensable 
for MHV. 
The data presented in this report provide information 
on the biosynthetic pathway of gp65 and also addi- 
tional details on the biosynthesis of El and E2. It is in- 
teresting that the three glycoproteins of MHV have 
different biosynthetic pathways. El is glycosylated via 
an 0glycosidic bond (Holmes et al., 1981; Niemann 
and Klenk, 1981) and is thus resistant to tunicamycin 
(Fig. 2). Our studies also suggest that its glycosylation 
occurs entirely within the Golgi complex. This conclu- 
sion is supported by the findings in this report that the 
glycosylation of El was inhibited by monensin, which 
interferes with protein transport in Golgi complex, and 
that glycosylation of El took nearly 2 hr to complete 
(Fig. 4), which is the length of time required for protein 
transport across Golgi. In contrast, E2 is glycosylated 
via an N-glycosidic bond, which occurs probably co- 
translationally (Niemann et al., 1982). Our study also 
showed that the final step of glycosylation of E2 occurs 
within Golgi complex, since monensin treatment re- 
duced the size of E2 (gp90), which was not detected 
until after 1 hr of chase period (Fig. 4). The data in this 
study suggest that gp65 is also glycosylated cotransla- 
tionally via an N-glycosidic bond. However, the glyco- 
sylation of gp65 is completed before the protein 
reaches cis-Golgi. This conclusion is supported by the 
findings that monensin did not affect the size of gp65 
and that a full-length gp65 was detectable after only 5 
min of labeling (Fig. 4). Interestingly, the pulse-chase 
Ml 2 3 456 
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FIG. 7. In v&o translation of the ORF 2b RNAs. Plasmid pT7(2b) 
was linearized with either EcoRI, generating a full-length transcript 
by T7 RNA polymerase, or BarnHI, generating a truncated 0.78-kb 
RNA. These RNAs were translated in rabbit reticulocyte lysates in the 
absence or presence of canine microsomal membrane. Aliquotes of 
the samples were treated with Pronase before applying to gels. M, 
“‘C-protein molecular markers; lane 1, EcoRI-generated transcript, 
without membrane; lane 2, EcoRI-generated transcript, with mem- 
brane; lane 3, BarnHI-generated transcript, without membrane; lane 
4, BarnHI-generated transcript with membrane; lane 5, EcoRI-gener- 
ated transcript, without membrane, Pronase-treated; lane 6, EcoRI- 
generated transcript, with membrane, Pronase-treated. 
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tional dichotomy during the evolution of viruses is inter- 
esting. Probably because of the hemagglutinin activity 
of gp65, BCV has been found to share the same recep- 
tor as influenza C virus (Vlasak eta/., 1988b). The ester- 
ase activity of BCV is also similar to the receptor-de- 
stroying enzyme of influenza C virus (Vlasak et al., 
1988a). The presence of gp65 in MHV may alter the 
tissue tropism, antigenicity, and pathogenicity of virus. 
Such a possibility is currently being studied. 
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experiment showed that gp65 underwent a trimming of 
carbohydrate chains during its transport across Golgi 
and that the trimming was not inhibited by monensin. 
This carbohydrate trimming is not observed with either 
El or E2. Thus, the maturation processes of the three 
glycoproteins of MHV appear to be different from each 
other. 
The detection of probably two unglycosylated pre- 
cursor proteins of gp65 is of considerable interest. 
These two protein species were seen in the in vitro 
translation products of purified mRNA 2b (Shieh el al., 
1989), in the precursor proteins accumulated in the 
presence of tunicamycin (Fig. 2), and in the endogly- 
cosidase H- or endoglycosidase F-treated protein (Fig. 
5). However, only one protein was detected in the in 
vitro translation product of ORF 2b RNA (Shieh et al., 
1989). These results suggest that there might be two 
different mRNA 2b species in JHM(2)-infected cells. We 
have examined three different isolates of JHM(2), all of 
which exhibited this heterogeneity of gp65 (data not 
shown). Thus, this heterogeneity is probably not 
caused by heterogeneity of virus population, but rather 
is the result of mRNA heterogeneity, which could be 
derived from alternative initiation or possible RNA edit- 
ing. The latter mechanism has been suggested from 
studies of P gene of paramyxoviruses (Thomas et al., 
1988). This possibility is particularly tempting since 
A59, which does not have a functional ORF 2b be- 
cause of the lack of an initiator AUG (Luytjes et al., 
1988) and does not have a consensus transcriptional 
initiation sequence (Shieh et a/., 1989), also synthe- 
sizes a small amount of gp65 (Fig. 1). The origin of 
gp65 in A59 strain and of gp65 heterogeneity in JHM 
strain is currently under study in our laboratory. 
Similar to BCV, the gp65 of JHM strain also contains 
an esterase activity. However, no hemagglutinin activ- 
ity was detected, in contrast to gp65 of BCV. This func- 
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